Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular response

DOI number 10.58109/fysg-ya55
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

Timothy Hughes (Institute of Medical and Veterinary Science)
Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 60 patients with chronic phase CML, utilising nilotinib plus pegylated interferon alfa-2b
  • Demographic data
  • Treatment data
  • Outcome data
  • Cancer Australia demographic data
    -Year of birth
    -Aboriginal or Torres Strait Islander status (or Ethnicity)
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Cancer therapy (excl. chemotherapy and radiation therapy)

Molecular targets
ANZCTR Reference ACTRN12612000851864
Publication(s)
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
CML09
CML12